Abstract 59P
Background
TPX-0131 is an ALK inhibitor developed for non-small lung cancer (NSCLC) patients that became resistant to first-line treatment. At the moment, pharmacokinetic data for TPX-0131 are still sparse. Therefore, we are interested to gain more insight into the pharmacokinetics of TPX-0131. Based on its structure and previously performed experiments with similar ALK inhibitors, TPX-0131 might be a substrate for the ABCB1, ABCG2, and OATP1 transporters and the CYP3A enzyme. Patients suffering from NSCLC often develop brain metastases. Therefore, the penetration of TPX-0131 into the brain is important to evaluate. Our main interest is therefore gaining more insight into the plasma pharmacokinetics (oral exposure) and the extent of brain penetration of TPX-0131.
Methods
An in vitro transwell experiment and in vivo experiments using genetically modified mouse models will be performed. With the use of a transmembrane in vitro transport assay, the potency of human ABCB1, human ABCG2 and murine Abcg2 to transport TPX-0131 will be evaluated. In vivo, the effect of ABCB1, ABCG2, OATP1 and CYP3A on the bioavailability and tissue distribution of TPX-0131 will be assessed. Different knockout and transgenic mouse models will be used for this purpose. The plasma concentration and tissue-to-plasma ratios of the genetically modified mouse models and wild-type mice will be compared after oral administration of 10 mg/kg TPX-0131.
Results
The in vivo data show that the brain concentration and brain-to-plasma ratio of TPX-0131 were significantly increased in the Abcb1a/b;Abcg2-/-compared to the wild-type mice. The plasma levels did not show any significant differences between these strains. Secondly, no significant differences could be observed between the Oatp1a/b-/- and wild-type mice. Furthermore, plasma levels appeared to be similar between Cyp3a-/-, Cyp3AXAV (expressing transgenic human CYP3A4 in liver and intestine in Cyp3a-/- background) and wild-type mice.
Conclusions
TPX-0131 might be a substrate for the ABCB1 and ABCG2 transporters. However, TPX-0131 is probably not a substrate for the OATP1 transporter(s) or the CYP3A enzyme.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Schinkel Group.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
38P - Locoregional radiotherapy improves survival outcomes in de novo metastatic nasopharyngeal carcinoma treated with chemoimmunotherapy
Presenter: Yujun Hu
Session: Cocktail & Poster Display session
Resources:
Abstract
40P - Development of radiolabelled plerixafor as a theranostic molecule for targeting CXCR4 receptor expressing cancers: A translational study
Presenter: Tamanna Lakhanpal
Session: Cocktail & Poster Display session
Resources:
Abstract
41P - BRCA2 pathogenic variant (PV): A novel agnostic biomarker for immune checkpoint blockers (ICB)?
Presenter: Beatriz Alonso de Castro
Session: Cocktail & Poster Display session
Resources:
Abstract
43P - Prognostic impact of the tumor immune microenvironment in adrenocortical cancer
Presenter: Nano Pachuashvili
Session: Cocktail & Poster Display session
Resources:
Abstract
44P - HPV16-specific CD4 and CD8 T-cell activation and functionality in patients receiving combination PDS0101 immunotherapy
Presenter: Lauren Wood
Session: Cocktail & Poster Display session
Resources:
Abstract
45P - Discovery of CBO-212, a first-in-class drug Fc-conjugate (DFC), targeting CD73 in cancer
Presenter: James Levin
Session: Cocktail & Poster Display session
Resources:
Abstract
48P - Efficacy analysis and mechanism exploration of furmonertinib for advanced NSCLC with EGFR exon 20 insertion mutation
Presenter: Xiao Zhang
Session: Cocktail & Poster Display session
Resources:
Abstract
49P - Treatment management in RAS and BRAF mutations in patients with metastatic colorectal cancer
Presenter: Merve Özkan
Session: Cocktail & Poster Display session
Resources:
Abstract
50P - KRAS mutation, the molecular landscape of lung adenocarcinoma in the Portuguese population
Presenter: Carolina Trabulo
Session: Cocktail & Poster Display session
Resources:
Abstract
51P - Toxicity profile in early clinical trials with fibroblast growth factor receptor (FGFR) inhibitors (FGFRi): 10-years experience of a drug development unit
Presenter: Katerin Rojas Laimito
Session: Cocktail & Poster Display session
Resources:
Abstract